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In the present paper, the controversial hypothesis suggesting ancient grains might show lower immunogenic properties and
therefore the possibility to introduce them in the diet of wheat-sensitive people, including celiac patients, was investigated.
The immunogenic potential of the ancient durum wheats Graziella Ra and Kamut was studied by comparison to the durum
accessions Cappelli, Flaminio, Grazia and Svevo. Experiments were carried out with two monoclonal antibodies (mAbs) raised
against α-gliadin peptides p31–49 and p56–75 (the latter containing the overlapping DQ2-Glia-α1 and DQ2-Glia-α2 epitopes),
toxic for celiac patients. For all accessions, a few α-gliadin alleles were also cloned, sequenced and translated into aminoacid
sequences. Several aminoacid substitutions or deletions were detected in p31–49, DQ2-Glia-α1 and DQ2-Glia-α2 epitopes,
nevertheless, ELISA constantly showed antibody-antigen positive reactions which led us to suggest that mAbs binding was
not apparently aﬀected by polymorphisms. Moreover, a few substitutions were also observed in DQ2-Glia-α3 and DQ8-Glia-
α1 epitopes. Although some DQ2-Glia-α1 and DQ2-Glia-α2 variants evidenced herein were previously reported to have a
diminished or abolished T cell stimulatory capacity, present results cannot conﬁrm that ancient durum wheats would be
less CD-toxic. In conclusion, we strongly advice celiac patients from consuming ancient wheats including Graziella Ra or
Kamut.
1.Introduction
Celiac disease (CD) is an intestinal chronic disorder caused
by an intolerance to wheat gluten proteins (gliadins and
glutenins) mainly resulting in small-intestinal mucosal
injuries and nutrient malabsorption in susceptible individ-
uals [1]. In recent years it has become clear that CD is far
more common than previously thought. Several serological
screening studies from Europe, South America, Australasia,
and the USA have shown that approximately 0.5–2% of these
populations suﬀers from CD. Nevertheless, most aﬀected
individualsremainundiagnosedduetoanincreasinglybroad
spectrum of clinical presentations [2]. Although they are all
characterized by a certain degree of villous atrophy, from a
clinical point of view, it is usual to consider three diﬀerent
forms of CD: major or classic CD (characterized by the
presence of symptoms of frank malabsorption, i.e., diarrhea,
steatorrhea, and/or weight loss); minor subclinical CD (with
no evident symptoms of malabsorption, but rather with
minor transient or extraintestinal symptoms); and Silent CD
(referringtopatientswithoutanyclinicalsymptomsatallbut
positive to serological tests such as antigliadin, antiendomys-
ial, and antitransglutaminase, showing evidence of histologi-
cal change in the small intestine). Hence, screening for silent
or subclinical CD has become of paramount importance,
especially considering that a proper diagnosis might prevent
and/or reduce the severity of symptoms and ultimately fa-
vour a remission of associated diseases.
CD is a multifactorial disorder including both genetic
and environmental factors whose relative weight is not yet
fully understood. Diﬀerences in concordance rates in mono-
zygotic (86%) and dizygotic (20%) twins strongly suggest a
relevant inﬂuence of genetic factors, of which HLA (Human
Leukocyte Antigen) is estimated to contribute for 40–50%2 The Scientiﬁc World Journal
to disease development [3, 4]. In particular, while roughly
95% of CD patients carries HLA-DQ2 (DQA1∗0501/DQB1∗
0201), most individuals that are not HLA-DQ2 positive
express HLA-DQ8 (DQA1∗0301/DQB1∗0302). Both HLA-
DQ2 and HLA-DQ8 have typical peptide-binding motifs
characterized by a preference for hydrophobic and negatively
chargedaminoacidsatspeciﬁcpositionsinpeptidesresulting
mostly from gliadins digestion [5, 6], although the celiac
toxicity of glutenins becoming increasingly appreciated [7].
According to mobility in lactic acid PAGE (A-PAGE),
gliadins can be subdivided into four subfractions: α/β-
gliadins, γ-gliadins, and ω-gliadins, whereas the glutenins
consist of low and high molecular weight (LMW and HMW)
glutenins, the latter being particularly important for the
baking quality of dough. Gliadins have several unique fea-
tures that contribute to their immunogenic properties.
They are extremely rich in proline (P) and glutamine (Q)
and, consequently, highly resistant to proteolytic degra-
dation within the gastrointestinal tract, since gastric and
pancreatic enzymes lack postproline-cleaving activities [8].
Additionally, the high-glutamine content makes gliadins a
good substrate for tissue transglutaminase (tTG), an enzyme
constitutively expressed in the lamina propria playing a role
in tissue repair. Under physiological conditions, tTG can also
convert (during the deamidation process) glutamine into the
negatively charged glutamic acid (E), leading to enhanced
immunogenicity of the resulting modiﬁed peptides, which
can preferentially bind to HLA-DQ2 or HLA-DQ8 [9, 10].
Deamidation is most likely a crucial event in the gener-
ation of a full-blown gluten-speciﬁc T-cell response and
concomitantCDdevelopment.ManyglutenpeptideswithT-
cell stimulatory capacity have been identiﬁed in all gliadin
fractions and in low and high molecular weight glutenins
[11, 12]. In particular, as far as concerns α-gliadins, four
peptides (with a minimal 9-mer epitope core), DQ2-Glia-
α1 [P(F/Y)PQPQLPY], DQ2-Glia-α2 (PQPQLPYPQ), DQ2-
Glia-α3 (previously reported as Glia-α20, FRPQQPYPQ),
and DQ8-Glia-α1 (QGSFQPSQQN) are known to provoke a
speciﬁcT-cellresponse.Inadditiontoagluten-speciﬁcT-cell
activation, there is also activity of the innate immune system,
mediatedbyinterleukin15(IL15)[13]whichmaybein voked
by gliadin peptides, particularly α-gliadin 31–49 (toxic core
LGQQQPFPPQQPY)thatdonotstimulatesmallintestinalT
cells [14]b u tw h i c hc a u s ein vitro [15, 16]a n din vivo celiac
toxicity [9].
The only eﬀective treatment available for CD patients is
a strict exclusion of gluten from the diet. Detrimental conse-
quences of gluten and/or analogous proteins (present in rye,
barleyandoats)consumptionarewelldocumented,showing
that noncompliance to a gluten-free diet is associated
with increased risk of anemia, infertility, osteoporosis, and
intestinal lymphoma [17]. On the other hand, complying
with a gluten-free diet is diﬃcult and aﬀects the patients’
quality of life, but a strict diet is critical to reduce morbidity
and mortality. New treatment strategies are thus actively
pursued. Most of these treatments aim to put the celiac
patients on a normal diet and add a drug designed to abolish
the T-cell stimulatory capacity of gluten. An alternative
possibility would be to improve the celiac diet with food
items made from baking-quality wheat that do not contain
harmful gluten proteins. In this regard, the existence of
thousands Triticum accessions has raised the question of
whether they are equally toxic for CD patients and promoted
attempts to generate (by selective breeding or genetic mod-
iﬁcations) wheat (and other cereals) with absent or reduced
immunogenicity [18, 19]. Moreover, ancient wheats (most
frequently not subjected to major genetic improvements)
have been speculated, although without any scientiﬁc or
clinical evidence, to potentially reduce or absent toxicity and
therefore to be better suited to be introduced into the diets
of people suﬀering from intolerances or allergies, including
celiac patients.
To test such a controversial hypothesis, the CD-immu-
nogenic properties of α-gliadins from two ancient wheats,
Graziella Ra; an historic accession of durum wheat showing
medium-high nutritional properties [20], and Kamut, con-
sidered an ancient relative of durum wheat, have been inves-
tigated by a comparative analysis with four durum wheats,
including Cappelli (the very ﬁrst selected Italian strain,
therefore considered a traditional wheat) and three modern
accessions, Flaminio, Grazia, and Svevo. In particular, as
a further step of a previous research aimed at evaluating
the genetic diversity of these accessions [21], in the present
paper we studied α-gliadin peptides p31–49 (LGQQQPFPP-
QQPYPQPQPF) and p56–75 (LQLQPFPQPQLPYPQPQL-
PY) by two complementary approaches based on standard
proteomic and genomic techniques. ELISA was carried out
using two speciﬁc monoclonal antibodies (mAbs), PN3 and
CDC-5, raised against synthetic peptides equivalent to the
aminoacids 31–49 and 56–75, respectively. A-gliadin genes
from all the accessions were also cloned and sequenced to
detect polymorphisms of the two toxic motifs and search
for a possible relationship between sequence variability and
monoclonal antibody/epitope binding reaction. Addition-
ally,α-gliadingenessequencesanalysisprovidedinformation
on DQ2-Glia-α3 and DQ8-Glia-α1 epitope variants.
2.MaterialsandMethods
2.1. Wheat Accessions and Gliadin Extraction. Graziella Ra
is a type of durum wheat characterized by low yield (15–
20 quintals per hectare), medium-long cycle, tall size (about
120cm), and a phenotype very similar to Kamut’s with large
ears and long aristas [20, 21]. It was brought to Italy at the
end of ‘70s, forgotten for a long time and “rediscovered”,
due to its ﬁne pasta-making qualities, a few years ago when
it appeared on the market as Graziella Ra. Kamut is a
registered trademark of Kamut International, Ltd., used in
marketing products made with the homonymous grain (cv.
QK-77), the correct subspecies of which is still in dispute.
In fact, according to Stallknecht et al. [22], Kamut has been
classiﬁed, from time to time, as T. turgidum polonicum, T.
turgidum turanicum, or T. turgidum durum;m o r er e c e n t l y ,
Khlestkinaetal.[23]suggestedthatKamutcouldbeanatural
hybrid between T. durum and T. polonicum. Although its
taxonomy is quite contentious, it is generally considered
an ancient relative of durum subspecies. Cappelli is anThe Scientiﬁc World Journal 3
Italian traditional strain of durum wheat which deserves
a privileged place among the varieties of old established
durum wheat for being the very ﬁrst selected variety. Svevo,
Grazia, and Flaminio are modern durum cultivars, with a
great commercial importance, employed for pasta or bread
making. All wheats were provided by Alce Nero Cooperative
(Isola del Piano, PU, Italy) with the exception of Kamut,
kindly supplied by Molini del Conero (Osimo, AN, Italy).
For each accession, wheat kernels were ground in an
electric grinder to produce a homogenous sample powder.
Subsequently, gliadins were extracted following standard
protocols: brieﬂy, 1g of powder was transferred to 10mL
of 60% (v/v) ethanol for 30min, shaking vigorously. After
centrifugation(3,000g ×15min)atroomtemperature(RT),
the supernatant was recovered and stored frozen (−20◦C).
Whole gliadin from Sigma-Aldrich (G3375) was employed
as standard.
2.2. Enzyme-Linked Immunosorbent Assay (ELISA). For each
accession, total gliadin was assessed by a commercial two
immunological step sandwich assay type, the Gliadin ELISA
kit(Immunotech)accordinglytothemanufacturer’sinstruc-
tions. Subsequently, α-gliadin was determined by indirect
two-steps ELISA with PN3 [24] and CDC-5 [25]m A b s
following standard procedures [26]. Brieﬂy, 96-microwells
plates were coated with samples (diluted 1:3,000) and stan-
dards (Sigma gliadin at concentrations ranging from 0ng/
mL to 1,000ng/mL) overnight at 4◦C in the dark, incubated
with murine mAbs (PN3, diluted 1:1,000 or CDC-5, diluted
1:2,000)foronehourandgoatanti-mouseimmunoglobulin
(IgG, H + L) conjugated to horseradish peroxidase (Pierce)
diluted 1:5,000, for one hour. The substrate, tetramethyl-
benzidine (TMB), was added to plates and after 15 minutes
at RT in the dark, absorbance was determined at 450nm.
Results were read oﬀ a semilogarithmic calibration curve.
Statistical analysis was performed by the one-way ANOVA
test, followed by the Bonferroni post hoc test.
2.3. DNA Extraction, Ampliﬁcation, Cloning, and Sequencing.
Fifteen seeds of each cultivar were germinated in the dark
for two days. The seedlings were grown in daylight for seven
days. The leaf tissues, sampled at the four-leaf stage from ten
diﬀerent plants per accession, were immediately frozen in
liquid nitrogen and ground in a mortar with a pestle. Fifty
mg of powder was used for DNA extraction following the
cetyltrimethylammonium bromide (CTAB) buﬀer protocol
[27] with slight modiﬁcations.
Forward (5 -ATGAAGACCTTTCTCATCC-3 )a n dr e -
verse (5 -YYAGTTRGTACCGAAGATGCC-3 )p r i m e r st o
amplify α-gliadin genes from genomic DNA were designed
on the conserved sequences at the 5  and 3  ends of the
coding region of a few α-gliadin gene complete sequences
retrieved from the GenBank database. PCR ampliﬁcation
was carried out using a high-ﬁdelity Pfu DNA Polymerase
(Promega) as follows: 95◦C for 2min; 95◦C for 1min,
60◦C for 30sec, 72◦C for 2min (30 cycles); 72◦C for 5min.
An aliquot (1μL) of the PCR product was inserted into






































































































Figure 1: Total gliadin and α-gliadin determination by indirect
ELISA. Total gliadin was assessed by a commercial kit (Immuno-
tech); α-gliadin was evaluated using anti-p31–49 (PN3) and anti-
p56–75 (CDC-5) mAbs. Results were read oﬀ a semilogarithmic
calibration curve, constructed as the dependence of measured
absorbance values (vertical axis—linear scale) of corresponding
calibrators (standard Sigma—gliadin), range 0–1,000ng/mL (hor-
izontal axis-logarithmic scale); values are reported as mean ± SD
from three independent experiments.
transformation was performed on Escherichia coli TOP10
cells following the manufacturer’s instructions (Invitrogen).
The selected transformants were analysed for presence
and correct orientation of the insert by PCR, grown in LB
medium overnight and puriﬁed by the Wizard Plus SV
minipreps kit (Promega). Sequencing of plasmid inserts
was done by using automated DNA sequencers at Euroﬁns
MWG Operon (Germany). Sequences were visualized with
BioEdit Sequence Alignment Editor version 7.0.5.3 [28],
aligned with the ClustalW option included in this software
and double checked by eye. Deduced aminoacid sequences
were obtained and analysed by BioEdit-dedicated options.
3. Results
3.1. ELISA. Kamut (K) (41.40 ± 0.10g/Kg) and Graziella
Ra (Gll) (40.43 ± 0.87g/Kg) had the greater amounts of
total (α/β, γ and ω) gliadin, followed by Cappelli (C)
(30.32 ± 1.06g/Kg), Flaminio (F) (26.80 ± 1.30g/Kg), Svevo
(S) (23.46 ± 4.67g/Kg), and Grazia (Gr) (23.04 ± 3.12g/Kg)
(Figure 1). One-way ANOVA showed means to be signiﬁ-
cantly diﬀerent (P<0.001), whereas the Bonferroni post
hoc test determined that Graziella Ra and Kamut were sig-
niﬁcantly diﬀerent from Flaminio (P<0.05), Grazia, and
Svevo (P<0.01) (Table 1).
For α-gliadin assayed using the PN3 (C, 4.09±0.41g/Kg;
F, 3.85 ± 0.02g/Kg; Gr, 3.66 ± 0.05g/Kg; Gll, 5.61 ±
0.19g/Kg; K, 5.80 ± 0.07g/Kg; S, 3.33 ± 0.39g/Kg) and
CDC-5 (C, 3.07 ± 0.25g/Kg; F, 2.88 ± 0.03g/Kg; Gr, 2.79 ±
0.2 0 g / K g ;G l l ,4 .25 ± 0.16g/Kg; K, 4.41 ± 0.30g/Kg; S,
2.84 ± 0.12g/Kg) mAbs (Figure 1) one-way ANOVA showed
diﬀerences among accessions to be statistically signiﬁcant
(P<0.001); results of Bonferroni correction are reported
in Table 1. All experiments gave similar outcomes for both4 The Scientiﬁc World Journal
Table 1: Results of Bonferroni multiple comparison post hoc test.
Accessions pairwise
comparisons
Statistical signiﬁcance of means
diﬀerences for total gliadin
Statistical signiﬁcance of means
diﬀerences for α-gliadin by PN3
Statistical signiﬁcance of means
diﬀerences for α-gliadin by
CDC-5
Cappelli versus Flaminio ns ns ∗∗∗
Cappelli versus Grazia ns ns ∗∗∗
Cappelli versus Graziella ns ∗∗
Cappelli versus Kamut ns ∗∗ ∗∗∗
Cappelli versus Svevo ns ns ∗∗∗
Flaminio versus Grazia ns ns ns
Flaminio versus Graziella ∗∗ ∗ ∗ ∗
Flaminio versus Kamut ∗∗ ∗ns
Flaminio versus Svevo ns ns ∗∗∗
Grazia versus Graziella ∗∗ ∗∗ ns
Grazia versus Kamut ∗∗ ∗∗ ns
Grazia versus Svevo ns ns ∗∗∗
Graziella versus Kamut ns ns ∗
Graziella versus Svevo ∗∗ ∗∗ ∗∗∗
Kamut versus Svevo ∗∗ ∗∗∗ ∗∗∗
Bonferroni method (one of the most common used post hoc test) was employed to compute the P values when comparing pairwise diﬀerences of mean values
for total gliadin (assessed by a commercial ELISA assay) and α-gliadin (assayed using PN3 and CDC-5 mAbs) amounts. ns, NOT SIGNIFICANT; ∗P<0.05;
∗∗P<0.01; ∗∗∗P<0.001.
mAbs showing an antibody-antigen-positive reaction in
every single case. Hence, according to mABs reactivity, all
grains under study, including the two ancient wheats, have
high potential immunogenicity and toxicity.
3.2. A-Gliadin Gene Sequences. A-gliadin genes from all the
accessions were cloned and sequenced. As already known
and in line with the relatively high-copy number of α-gliadin
alleles reported for diploid wheat ancestors (T. speltoides and
T. monococcum) and hexaploid (T. aestivum)s p e c i e s[ 29],
in this study as well, several alleles, identiﬁed as short (S)
or long (L), were characterized diﬀering from each other,
at least in this case, mostly in the length of few CAA-rich
regions.Sallelesrangedfrom828bpto867bp,whileLalleles
were between 894bp and 963bp. Every accession showed at
leastonealleleofeachtype.Moreover,consistentpercentages
of α-gliadin alleles containing one or more internal stop
codons (C→T substitution was the most common single-
base change observed) were encountered. In line with other
studies, we refer to them as pseudogenes, although we
cannot predict from the genomic data whether a subset
is being expressed [30]. Such ﬁndings agree with previous
observations that at least 50% of the α-gliadin genes is pseu-
dogenes [29, 31].
All sequences were submitted to GenBank database
(GQ999806–GQ999831). Each allele was translated (with a
BioEdit dedicated option) into the corresponding protein.
Deduced aminoacid sequences showed a high degree of
similarity (about 75% and 86% for S and L isoforms, resp.).
Protein alignment displayed the two epitope motifs (p31–
49 and p56–75) in all aminoacid sequences, although with
a large series of variants (Table 2; Figure 2). Polymorphisms
mainlyincludedoneortwoaminoacidsubstitutions(inp31–
49, DQ2-Glia-α2, DQ2-Glia-α3 and DQ8-Glia-α1) and a
deletion of Q at p2 (in DQ2-Glia-α2) or at p4 (in DQ2-
Glia-α1). Namely, (1) p31–49 variants included L1→P, P6→
Q, Y13→D, P16→A, and P18→T; (2) DQ2-Glia-α1 variants
included a deletion of Q at position 4 (observed only in
epitopes from locus Gli-B2) and the substitution Y9→H; (3)
DQ2-Glia-α2 variants included the substitution P8 →S( a l l
in epitopes from locus Gli-A2), Y7→H and a deletion of Q
at position 2, epitopes showing the deletion at p2 were from
locus Gli-B2; (4) DQ2-Glia-α3 variants included R2 →Po r
R2→S, P3→T, Y7→Ia n dP 8→So rP 8→L; (5) DQ8-Glia-α1
variants included the aminoacid substitutions G2→V, S3→F,
Q5→Wo rQ 5→R, and Q9→L.
4. Discussion
Celiac disease, a prototype of T-cell-mediated diseases, is
caused by a combination of adaptive and innate immune
responses. Generally speaking, T (and B) cells are part of
the adaptive immune system, which is characterized by
the ability to recognize and remember previous speciﬁc
antigenic pathogens and adapt its response with time. T
cells recognize antigens in the context of MHC molecules,
normallydisplayed bya set of specialized cellscalledantigen-
presentingcells.However,themererecognitionoftheMHC-
antigen complex is not suﬃcient to induce a protective T-cell
immune response; in fact, T cells have to recognize antigen
in the context of an activated innate immune system (i.e.,
the nonspeciﬁc immune system and ﬁrst line of defense).The Scientiﬁc World Journal 5
Table 2: p31–49, DQ2-Glia-α1, DQ2-Glia-α2, DQ2-Glia-α3, and DQ8-Glia-α1 epitopes variants detected in durum wheats under study.
Accession Locus p31–49 DQ2-Glia-α1 DQ2-Glia-α2 DQ2-Glia-α3 DQ8-Glia-α1
Cappelli L Gli-A2 cs cs PQPQLPYSQc sQ VSFQPSQLN
Cappelli S Gli-A2 LGQQQPFPPQQPYPQPQTF PFPQPQLPH PQPQLPHSQ FRPQQPISQQ G S F RPSQQN
Flaminio L Gli-B2 PGQQQQFPPQQPYPQPQPF PFP-PQLPY P-PQLPYPQ FPPQQPYPQ QVSFQPSQLN
Flaminio S Gli-B2 PGQQQPFPPQQPYPQPQPF PFP-PQLPY P-PQLPYPQ FSPQQPYPQ cs
Grazia L Gli-B2 PGQQQQFPPQQPYPQPQPF PFP-PQLPY P-PQLPYPQ FPPQQPYPQ QVFFQPSQLN
Grazia S Gli-A2 LGQQQQFPPQQPDPQPQPF cs PQPQLPYSQ FRPQQPYLQQ G FFRPSQQN
Graziella L Gli-B2 PGQQQPFPPQQPYPQPQPF PFP-PQLPY P-PQLPYPQ FPTQQPYPQ QVSFQPSQLN
Graziella S Gli-B2 PGQQQPFPPQQPYPQPQPF PFP-PQLPY P-PQLPYPQ FPTQQPYPQ QGSFQPSQLN
Kamut L Gli-B2 PGQQQQFPPQQPYPQPQPF PFP-PQLPY P-PQLPYPQ FPPQQPYPQ QVSFQPSQLN
Kamut S Gli-A2 LGQQQPFPPQQPYPQAQPF cs PQPQLPYSQc sQ G S F WPSQQN
Svevo L Gli-B2 PGQQQQFPPQQPYPQPQPF PFP-PQLPY P-PQLPYPQ FPPQQPYPQ QVSFQPSQLN
Svevo S Gli-B2 PGQQQQFPPQQPYPQPQPF PFP-PQLPY P-PQLPYPQ FSPQQPYPQ QGFFQPSQQN
Canonical sequences (cs), p31–49: L1G2Q3Q4Q5P6F7P8P9Q10Q11P12Y13P14Q15P16Q17P18F19;D Q 2 - G l i a - α1: P1(F/Y)2P3Q4P5Q6L7P8Y9;D Q 2 - G l i a - α2:
P1Q2P3Q4L5P6Y7P8Q9;D Q 2 - G l i a - α3: F1R2P3Q4Q5P6Y7P8Q9;D Q 8 - G l i a - α1: Q1G2S3F4Q5P6S7Q8Q9N10. In bold underlined: aminoacid substitution;
hyphen: aminoacid deletion.
In celiac disease, gliadin acts as an antigen recognized by
the CD4+ T cells and, moreover, has the ability to induce
an activation of the innate immune response as well [16].
Hence, although the adaptive immune system is central
to the development of celiac disease, adaptive immune re-
sponses are, however, controlled by an earlier activation of
theinnateimmunesystemtriggeredbyafragmentofgliadin.
Key steps underlying the intestinal inﬂammatory response
to CD include (1) a direct response of the epithelium via
the innate immune system to toxic proteins in wheat gluten,
(2) modiﬁcation of wheat gluten proteins by tissue trans-
glutaminase, (3) the role of HLA-DQ2 and HLA-DQ8 in
presenting toxic wheat proteins to T cells, and (4) activation
of T and B cells [1].
Several T-cell stimulatory α-gliadin peptides have been
identiﬁed, DQ2-Glia-α1 [P(F/Y)PQPQLPY], DQ2-Glia-α2
(PQPQLPYPQ), DQ2-Glia-α3 (FRPQQPYPQ), and DQ8-
Glia-α1 (QGSFQPSQQN), showing a large diversity of natu-
ral variants, many of which have T-cell stimulatory activity
[32]. An additional α-gliadin peptide, known as p31–49,
has been reported to activate the innate immune system by
playing an important role as danger signal. It is not the
target of gluten-speciﬁc T cells but does induce changes
associated with CD on administration in vivo and during
biopsy challenges in vitro. It has also been shown that prein-
cubation of biopsy specimens of CD patients with the 31–49
peptide enabled T-cell activation. These eﬀects were found
to correlate with the induction of IL-15, a cytokine that is
crucial for the activation and survival of memory T cells
and induces epithelial changes. Moreover, IL-15 production
by enterocytes could have an eﬀect on the adaptive immune
response to gluten [13].
In the present study, we characterized α-gliadin from
Graziella Ra and Kamut in order to investigate (by molecular
analyses and inspection of translated aminoacid sequences)
the hypothesis suggesting that ancient grains might show
lower immunogenic properties and therefore the possibility
to introduce them in the diet of wheat-sensitive people,
including celiac patients. To this aim, α-gliadin main toxic
peptides related to CD, p31–49 (LGQQQPFPPQQPYPQ-
PQPF) and p56–75 (LQLQPFPQPQLPYPQPQLPY), were
analysed in two ancient durum wheats and in four durum
varieties (Cappelli, Flaminio, Grazia, and Svevo) by two dif-
ferent approaches. A ﬁrst level of analysis was performed
by ELISA to evaluate wheat toxicity by speciﬁc mAbs raised
against the immune-reactive peptides. Subsequently, amino-
acid mutations (substitutions and/or deletions) in the toxic
motifs, including DQ2-Glia-α3 and DQ8-Glia-α1, were ex-
amined.
By using a commercially available gluten test kit, we de-
termined that Graziella Ra and Kamut have relatively greater
amount of gliadin than Cappelli, Grazia, Flaminio, and
Svevo. Taking into account that gluten, about 80% of the
entire protein reservoir in wheat, is composed by gliadins
and glutenins, present results would validate the producers’
claims that ancient wheats are endowed with kernels usually
bigger and richer in proteins than modern wheats. Inter-
estingly, Cappelli showed an amount of gliadin that is in-
between ancient and modern accessions, which supports the
placing it as a traditional wheat. When employing a two-
step indirect ELISA with PN3 and CDC-5 mAbs, p31–49
and p56–75 were observed in all accessions. In particular,
GraziellaRaandKamutshowedthehighestvalues(expressed
as α-gladin amount), thus challenging the “low-immuno-
genicity” hypothesis. These ﬁndings point out that, in our
study, ancient wheats have greater amounts of both total
and α-gliadin than modern accessions; moreover, taking into
account that α-gliadins from ancient wheats showed a strong
and speciﬁc binding reaction to anti-p31–49 and anti-p56–
75mAbs,theseaccessionsmaybeconsidered,atleast,astoxic
as modern ones.
Al a r g es e r i e so fα-gliadin epitope variants, mainly con-
sisting of one or two aminoacid substitutions (Table 2)w e r e
detected in all the accessions (including ancient ones). Al-
though their T-cell stimulatory capacity would need to be
further investigated, nevertheless, the immunogenic prop-
erties of (at least) some of them may be discussed in the
light of recently published data. In our study, in fact, we6 The Scientiﬁc World Journal
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Figure 2: Alignment of deduced L and S α-gliadin isoforms of each wheat accession under study. The ﬁve epitopes known to be
involved in CD, p31–49 (LGQQQPFPPQQPYPQPQPF), DQ2-Glia-α1 [P(F/Y)PQPQLPY], DQ2-Glia-α2 (PQPQLPYPQ), DQ2-Glia-α3
(FRPQQPYPQ), and DQ8-Glia-α1 (QGSFQPSQQN) are shown in red. In light grey: aminoacid substitution; hyphen and light grey:
aminoacid deletion. For each α-gliadin isoform the signal peptide is in light blue.
did encounter several variants which, according to Mitea
et al. [32], have a diminished or abolished T-cell stimulatory
capacity. These include (1) aminoacid deletion at p4 in DQ2-
Glia-α1 (Flaminio, Grazia, Graziella Ra, Kamut, and Svevo);
(2) a single substitution of the proline for a serine residue
(P→S) at p8 in DQ2-Glia-α2 (Cappelli, Grazia and Kamut);
(3) an arginine to proline substitution (R→P) at p2 in DQ2-
Glia-α3 (Flaminio, Grazia, Graziella Ra, Kamut and Svevo);
(4) a single serine to phenylalanine substitution (S→F) at
p3 (Grazia and Svevo S); a single glutamine to arginineThe Scientiﬁc World Journal 7
substitution (Q→R) at p5 (Cappelli, Grazia) in DQ8-Glia-
α1. As far as concerns the other epitope variants reported in
the present paper, several have never been described before
while some have been described but never tested for their
T-cell stimulatory capacity. Granted that accessions under
study would deserve a deeper investigation to verify and
evaluate their immunogenic capacity, on the other hand,
ELISA results (with PN3 and CDC-5 mAbs) demonstrated
that detected polymorphisms do not (or little) seem to aﬀect
the binding of the monoclonal antibodies to their targets.
I nf a c t ,b o t hm A b sg a v ei n t e n s ep o s i t i v er e a c t i o n sf o ra l l
wheats (including ancient ones). Such a ﬁnding might be
due to the fact that these variants are not contained within
the motif recognized by the mAb or, alternatively, although
being inside the region, they do not signiﬁcantly inﬂuence
the binding reaction. For instance, PN3, which has been
shown to bind in the region QQQPFP of the peptide p31–
49 [24], in the present study apparently reacted to the
QQQQFP variant as well. As far as concerns the eﬀect of
DQ2-Glia-α1 and DQ2-Glia-α2 variants on CDC-5 binding
reaction, the issue remains unclear since, unfortunately, the
exact sequence within the T-cell stimulating peptide p56–75
identiﬁed by the antibody CDC-5 is not known at present.
Further studies will be necessary to address this question
and evaluate how sensitive CDC-5 is in discriminating DQ2-
Glia-α1andDQ2-Glia-α2variants.Although,atthemoment
we can provide the reader with indirect evidence on the T-
cellstimulatorycapacityofCappelli,Flaminio,Grazia,Svevo,
Graziella Ra, and Kamut α-gliadins, however, even if the
above discussed variants were conﬁrmed, by T-cell prolif-
eration assays, to have weak (or absent) T-cell stimulatory
properties, all wheats herein examined would still not be safe
for CD patients since, besides α-gliadins, many other gluten
proteins (i.e., γ-a n dω-gliadins, HMW and LMW glutenins)
contain stimulatory peptides (relevant to CD pathogenesis)
recognized by a heterogeneous repertoire of intestinal T-cell
responses [33].
In conclusion, our results demonstrate that (1) the
ancientwheatsGraziellaRaandKamuthavegreateramounts
of total and α-gliadin than modern accessions; (2) α-gliadins
from such ancient wheats show a strong and speciﬁc binding
reaction to anti-p31–49 and anti-p56–75 mAbs; (3) the
(putatively) less toxic variants of p31–49, DQ2-Glia-α1a n d
DQ2-Glia-α2 epitopes detected in all accessions, including
ancient wheats, do not seem to aﬀect mAbs/epitope binding
reactions. Therefore, we suggest that Graziella Ra and Kamut
are potentially as toxic as modern wheats with reference
to CD and strongly recommend that they should not be
introduced in the diet of celiac patients.
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